Voxzogo
What Voxzogo is used for
Voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Voxzogo
- Active substance
- vosoritide
- Disease area
- Achondroplasia
- Medicine group
- Drugs for treatment of bone diseases
- ATC code
- M05BX
- Marketing authorisation holder
- BioMarin International Limited
- Authorised in the EU since
- 2021
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Voxzogo used for?
Voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
What is the active substance in Voxzogo?
Voxzogo contains vosoritide.
Who makes Voxzogo?
The EU marketing authorisation holder is BioMarin International Limited.
Is Voxzogo an orphan medicine?
Yes. Voxzogo is designated an orphan medicine in the EU, for a rare disease (Achondroplasia).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU